Brief: Opthea Announces To Receive US$35M Commitment And Additional US$50M Funding
27/12/2023 24:48
Dec 27 (Reuters) - Opthea Ltd OPT.AX :
* OPTHEA TO RECEIVE US$35M COMMITMENT AND ADDITIONAL US$50M
FUNDING
* FUNDING WILL BE USED TO ADVANCE OPTHEA'S PHASE 3 CLINICAL
TRIALS
AND PRE- COMMERCIALIZATION ACTIVITIES OF SOZINIBERCEPT FOR WET
AMD
Source text for Eikon: ID:nASXbQZ75N
Further company coverage: OPT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ceryvyn Therapeutics
See all newsBrief: Ceryvyn Therapeutics Posts FY Profit Attributable A$330.4 Million
Brief: Opthea To Recommence Trading On ASX On Or Around June 3, 2026
Brief: Opthea Says Hamish George Assumes Role Of CFO
Brief: Opthea Logs FY Prelim Loss Attributable $162.8 Mln
Australia's Opthea cuts 80% staff, key executives to exit in deal to avert bankruptcy (updated)